# Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Source: https://onco.cc/trials/nct06995677/  
OnCo record `nct06995677` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TYRA-300 in bladder & urothelial cancer, run by Tyra Biosciences, Inc, now recruiting.

## Summary

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer is a phase 2 interventional study registered as NCT06995677 by Tyra Biosciences, Inc, with 90 participants planned, started 2025-06-27 and due to reach its primary completion in 2028-02. Interventions recorded: TYRA-300 60mg, TYRA-300 50mg and TYRA-300 Dose TBD.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06995677
- Phase: 2
- Setting: A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
- Sponsor: Tyra Biosciences, Inc
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06995677: https://clinicaltrials.gov/study/NCT06995677

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [TYRA-300](https://onco.cc/drugs/tyra-300/)
- companies: [Tyra Biosciences](https://onco.cc/companies/tyra-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06995677.json